Azurity Pharmaceuticals Receives FDA Approval for XIFYRM™ Injection to Manage Severe Pain in Adults

FDA Approval of XIFYRM™

Azurity Pharmaceuticals, Inc., headquartered in Woburn, Massachusetts, has made headlines with the recent approval from the U.S. Food and Drug Administration (FDA) for its novel product, XIFYRM™ (meloxicam injection). This innovative intravenous (IV) medication is classified as a non-steroidal anti-inflammatory drug (NSAID) and is designed for adult patients who experience moderate-to-severe pain.

The approval opens a new avenue for healthcare providers as XIFYRM is indicated for use either solely or alongside non-NSAID analgesics. The product comes in a 30mg/mL vial and can be administered via a 15-second IV bolus injection, providing flexibility in pain management strategies. Remarkably, XIFYRM allows for once-daily dosing, making it not only effective but also convenient for both patients and healthcare providers.

Ron Scarboro, the CEO at Azurity Pharmaceuticals, emphasized the company's dedication to enhancing patient care through innovative solutions. "XIFYRM demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," remarked Scarboro. He added, "XIFYRM addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies." This statement underscores Azurity's focus on providing alternatives to opioids, a growing necessity in today’s medical landscape.

While the approval marks a milestone for Azurity, it is crucial to note that XIFYRM is not recommended for situations requiring rapid onset of analgesia due to its delayed onset of action. This factor highlights the importance of healthcare clinicians in carefully assessing the needs and conditions of patients before prescribing this medication.

XIFYRM is set to be available in the coming weeks, allowing for public access to this important addition in the arsenal for pain management. For those interested in learning more, complete prescribing information, including boxed warnings and safety profiles, can be found at www.xifyrm.com.

About Azurity Pharmaceuticals

Azurity Pharmaceuticals is a privately held company focused on delivering innovative, high-quality medicines specifically designed for underserved patient populations. With a global presence spanning over 50 countries, Azurity boasts a diverse portfolio featuring more than 30 marketed brands, each addressing critical therapeutic areas across ten different dosage forms. The company leverages a Next-Gen Commercial Model that includes data analytics and AI-driven tools to enhance market outreach and stakeholder engagement, ultimately benefitting millions of patients with their products.

For further details on Azurity Pharmaceuticals and its offerings, visit www.azurity.com.